OPKO Health, Inc. Impairment of Intangible Assets, Finite-lived
OPKO Health, Inc. (OPK) reported Impairment of Intangible Assets, Finite-lived of $1.01 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsFinitelived · last filed 2026-02-26
- OPKO Health, Inc. impairment of intangible assets, finite-lived for the quarter ending 2025-12-31 was $0.00.
- OPKO Health, Inc. impairment of intangible assets, finite-lived for the quarter ending 2024-12-31 was $0.00.
- OPKO Health, Inc. impairment of intangible assets, finite-lived for fiscal 2025 was $1.01M.
- OPKO Health, Inc. impairment of intangible assets, finite-lived for fiscal 2024 was $0.00.
- OPKO Health, Inc. impairment of intangible assets, finite-lived for fiscal 2023 was $0.00.
- OPKO Health, Inc. impairment of intangible assets, finite-lived for fiscal 2022 was $0.00.
| Period end | Impairment of Intangible Assets, Finite-lived 3 month | Impairment of Intangible Assets, Finite-lived 9 month | Impairment of Intangible Assets, Finite-lived 12 month |
|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.01M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $1.01M 10-Q · filed 2025-10-29 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 | |
| 2024-09-30 | $0.00 10-Q · filed 2025-10-29 | ||
| 2023-12-31 | $0.00 10-K · filed 2026-02-26 | ||
| 2022-12-31 | $0.00 10-K · filed 2025-03-03 | ||
| 2021-12-31 | $0.00 10-K · filed 2024-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |